Decision on the annual renewal of the conditional marketing authorisation for the medicinal product for human use "Veklury - remdesivir

This procedure concerns an objection to the European Commission's decision to renew the marketing authorisation for the human medicinal product Veklury, which contains remdesivir. This is a formal step in the legislative process.

This objection affects patients who may use Veklury, healthcare providers, and the pharmaceutical company involved. It triggers a debate and potential vote in Parliament on the product's authorisation.